Equities

Standard BioTools Inc

Standard BioTools Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)2.11
  • Today's Change0.08 / 3.94%
  • Shares traded1.00
  • 1 Year change-26.74%
  • Beta1.5816
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. The Company's segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The Company provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company also provides differentiated multi-omics tools for research.

  • Revenue in USD (TTM)136.30m
  • Net income in USD-164.66m
  • Incorporated2007
  • Employees534.00
  • Location
    Standard BioTools Inc2 Tower Place, Suite 2000SOUTH SAN FRANCISCO 94080United StatesUSA
  • Phone+1 (650) 266-6000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.standardbio.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
LAB:NSQ since
announced
Transaction
value
SomaLogic IncDeal completed04 Oct 202304 Oct 2023Deal completed-21.85%565.42m
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Paragon 28 Inc235.44m-59.07m574.51m430.00--3.91--2.44-0.7132-0.71322.841.760.77030.60496.63547,539.60-19.33---23.48--76.67---25.09--1.70-5.300.4295--19.30--28.94------
Quanterix Corp129.33m-39.71m594.49m441.00--1.77--4.60-1.04-1.043.408.770.30782.374.60293,265.30-9.45-15.96-10.30-17.6657.4252.79-30.71-53.798.99--0.00--15.9626.6066.56--20.07--
Orthofix Medical Inc771.65m-120.49m611.73m1.63k--1.14--0.7928-3.21-3.2120.5514.350.86541.176.49472,245.40-13.51-8.88-16.22-10.9667.1872.37-15.62-9.281.13-4.940.2005--62.0610.51-666.60--30.01--
Iradimed Corp69.48m18.64m623.73m148.0033.657.8332.048.981.461.465.456.290.81091.556.03469,485.3021.7613.1623.8514.5877.2176.5526.8321.468.25144.050.0068.1323.0016.5934.0222.2297.77--
AxoGen Inc173.48m-16.54m642.98m426.00--6.72--3.71-0.3829-0.38294.012.180.91171.627.43407,237.10-8.69-13.92-9.93-15.8476.9879.74-9.53-20.282.32-2.940.3297--14.7413.6324.98--17.70--
Simulations Plus Inc66.98m9.65m645.45m192.0068.053.5745.649.640.4740.4743.299.040.3603--5.57348,843.805.197.205.497.6172.5377.6114.4021.29----0.0045.7010.5214.96-20.206.0212.910.8548
SI-Bone Inc150.71m-40.85m660.02m344.00--3.99--4.38-1.00-1.003.703.970.65861.546.67438,107.60-17.85-27.88-19.57-30.9477.6985.03-27.10-51.098.12--0.18--30.5220.1929.25--52.62--
Mesa Laboratories Inc223.71m-250.31m694.70m736.00--4.61--3.11-46.43-46.4341.4327.870.41312.516.29303,956.50-46.23-9.20-50.62-9.8862.2760.60-111.89-28.331.371.330.5848---1.3215.95-27,438.28--15.260.00
Cytek Biosciences Inc197.71m-17.56m695.66m645.00--1.79--3.52-0.1327-0.13271.492.960.3921.544.19292,470.40-3.48---3.89--54.97---8.88--6.38--0.0083--17.67---571.58------
Orthopediatrics Corp175.07m-25.12m707.30m247.00--1.91--4.04-1.10-1.107.6515.330.40450.42864.61708,793.50-5.80-5.40-6.43-5.9374.6275.09-14.35-15.921.96-44.230.0261--21.6220.91-1,767.25--28.29--
Standard Biotools Inc136.30m-164.66m783.14m534.00--1.53--5.75-0.9018-0.90180.66061.370.25612.255.73255,243.50-22.29-28.17-26.55-33.6046.6751.58-87.05-74.853.53--0.0974--8.57-1.2060.73--50.06--
Castle Biosciences Inc287.59m-3.10m846.80m610.00--2.0084.792.94-0.1346-0.134610.4515.300.63027.387.44471,457.40-0.6791-9.43-0.7383-10.1781.8680.58-1.08-28.467.92--0.0238--60.3857.3514.41--117.94--
Alphatec Holdings Inc540.28m-180.91m872.26m839.00--51.90--1.61-1.34-1.344.000.28470.77361.137.30643,959.50-25.90-30.97-33.24-39.4769.4466.02-33.48-46.221.21-4.590.9273--37.4539.38-23.36--67.92--
Embecta Corp1.12bn69.70m906.50m2.20k13.02--8.370.81021.211.2119.36-13.240.88822.1111.60508,590.905.53--7.91--66.42--6.23--1.612.061.88---0.7703---68.52------
Bioventus Inc536.89m-41.96m938.48m1.03k--6.22--1.75-0.6595-0.65958.481.860.65911.954.18553,495.90-6.70-5.52-9.65-7.2766.5368.25-10.16-10.940.9561.080.6697--0.04459.936.91--23.51--
Figs Inc550.80m18.68m961.94m354.0054.722.3943.121.750.10290.10293.042.351.181.2358.021,555,932.003.99--4.65--68.02--3.39--3.89--0.00--7.87--6.85------
Data as of Sep 19 2024. Currency figures normalised to Standard BioTools Inc's reporting currency: US Dollar USD

Institutional shareholders

60.13%Per cent of shares held by top holders
HolderShares% Held
Casdin Capital LLCas of 27 Aug 202474.04m19.95%
Viking Global Investors LPas of 30 Jun 202458.65m15.80%
BlackRock Fund Advisorsas of 30 Jun 202419.60m5.28%
The Vanguard Group, Inc.as of 30 Jun 202415.52m4.18%
ARK Investment Management LLCas of 30 Jun 202412.68m3.42%
Morgan Stanley Investment Management, Inc.as of 30 Jun 202412.48m3.36%
Nikko Asset Management Americas, Inc.as of 30 Jun 202410.64m2.87%
Geode Capital Management LLCas of 30 Jun 20246.79m1.83%
Tikvah Management LLCas of 30 Jun 20246.55m1.77%
Millennium Management LLCas of 30 Jun 20246.22m1.68%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.